Cancer Research

Cancer tumour
#Biotechnology #Cancer research #iOnctura #Tumours

New research highlights potential of combination cancer treatment 

iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumour survival pathways, has published new research data in the peer-reviewed journal Cancer Research, that supports a strategy of combining autotaxin inhibitor IOA-289 with TGF-β pathway inhibitor IOA-359.   Resistance to TGF‐β… Read More

#Cancer Research #News

Vaccine vial and syringe
#Cancer research #Cancer vaccine #DDW Turning Science into Business Summit #Events #Immunology / Virology & Vaccines #Oncology #Webinar

DDW Cancer Research Summit: Insight on cancer vaccines

The DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’ will take place online on 16 November at 7AM PST / 10AM EST / 3PM GMT / 4PM CET. This free summit, sponsored by Taconic Biosciences, will offer expert thought leadership… Read More

#Cancer Research #News

Saline intravenous (iv) drip in a child's hand
#Charles River #Human disease models #Oncology #Paediatrics #Preclinical investigations

Paediatric models for preclinical testing of oncology drugs

The US Food and Drug Administration’s (FDA) Research to Accelerate Cures and Equity (RACE) for Children Act now requires all oncology drugs to be tested for paediatric indications ahead of approval. The EU regulation of the European Medicines Agency (EMA) is also being adapted to mirror… Read More

#Cancer Research #News

Prostate cancer cells
#Drug resistance #Oncology #Prostate cancer #The Institute of Cancer Research #The Institute of Oncology Research #The Royal Marsden NHS Foundation Trust

Researchers reverse prostate cancer drug resistance

Prostate cancer’s resistance to treatment can be reversed in some patients by stopping hijacked white blood cells from being ‘pulled into’ tumours, according to new research published in Nature. In an early clinical trial, researchers showed that blocking the messages cancer uses to hijack white blood… Read More

#Cancer Research #News #Trending News

CAR-T therapy
#Cancer research #CAR-T #CARsgen Therapeutics #China #Oncology #Solid tumours

CAR T therapy successfully treats solid tumours in China

CARsgen has published evidence of over seven years of disease-free survival in advanced hepatocellular carcinoma (HCC) following treatment with its CAR-GPC3 T cell therapy. Hepatocellular carcinoma is one of the most common malignant tumours, with approximately 780,000 annual incidence cases globally. Recurrence and metastasis are common. Read More

#Cancer Research #Editor's Choice #News

Cancer research
#Cancer research #DDW Turning Science into Business Summit #Oncology #Webinar

DDW Cancer Research Summit: Strategies to get to market faster

The DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’ will feature experts and thought leaders in cancer research, precision medicine and immunotherapy. Andreas Dreps DDW is delighted to confirm that ICON’s SrVP and Global Head of Science Andreas Dreps and… Read More

#Cancer Research #News

Gastric cancer
#Antibody #FDA #Gastrointestinal #Oncology #Phase III trial #Stomach cancer #Transcenta

Antibody for gastric cancer progresses to Phase III trials

The US Food and Drug Administration (FDA) has granted clearance to Transcenta to proceed with its TranStar 301 global Phase III pivotal trial of Osemitamab (TST001) for gastric cancer. The trial will investigate the drug in combination with Nivolumab and chemotherapy as a first-line treatment in patients with HER2-negative, CLDN18.2… Read More

#Cancer Research #News #Regulatory

IgG1 monoclonal antibody
#Artificial intelligence (AI) #Aulos Bioscience #Monoclonal antibodies #Oncology #Phase I trial #Solid tumours

Data supports IgG1 monoclonal antibody for solid tumours

Aulos Bioscience has revealed new safety and efficacy data from the Phase I dose escalation portion of its Phase I/II clinical trial of AU-007 in patients with unresectable locally advanced or metastatic solid tumour cancers. The data will be presented at the Society for Immunotherapy of… Read More

#Cancer Research #News

Non-small cell lung cancer
#Gene therapy #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology #Phase I trial

Non-viral gene therapy shows early efficacy in lung cancer

Positive Phase I trial data indicates that Reqorsa (quaratusugene ozeplasmid) has shown early efficacy for the treatment of non-small cell lung cancer (NSCLC). The data will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. Developed by… Read More

#Cancer Research #News

Cancer research
#Cancer drug targets #Cancer research #DDW Turning Science into Business Summit #Drug discovery #Events #Immunotherapy #Oncology

DDW announces Summit on advances in cancer research

Join DDW’s Megan Thomas and Reece Armstrong with sponsor Taconic Biosciences for the first DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’, on 16 November at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. This free 2-hour… Read More

#Cancer Research #News

Research laboratory
#Cancer research #Collaboration #Merck #Oncology #The Institute of Cancer Research

ICR and Merck renew cancer drug discovery alliance

Merck and The Institute of Cancer Research (ICR), London, UK, have renewed their strategic alliance in the discovery and development of new cancer drugs. Scientists in the Centre for Cancer Drug Discovery at the ICR will work with researchers at Merck to discover and develop new… Read More

#Cancer Research #News

Cancer metastasis
#Cancer drug targets #Cancer research #Drug resistance #Oncology #University of Queensland

Novel inhibitors could become new anticancer therapeutics

University of Queensland (UQ) researchers have identified a novel drug target with the potential to overcome drug resistance and prevent tumour regrowth in cancer patients. The newly identified molecule is not currently a target for treatment, opening the potential for drug development. “Drug resistance… Read More

#Cancer Research #News

CAR-T therapy
#Cancer research #CAR-T #Leucid Bio #MHRA #Oncology #Solid tumours

CAR-T therapy targets over 80% of human tumours

Leucid Bio has been granted clinical trial authorisation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I/II clinical trial evaluating autologous NKG2D-targeted CAR-T cell therapy, LEU011, in patients with relapsed or refractory solid tumours. The open-label, single patient cohort ascending… Read More

#Cancer Research #Editor's Choice #News

T cells
#Cancer research #CAR-T #Immunotherapy #Oncology #T cell activation #Umoja Biopharma

Positive early-stage results for in vivo CAR-T technology

Umoja Biopharma has revealed data from an ongoing non-human primate (NHP) study demonstrating effective, durable, and well tolerated in vivo chimeric antigen receptor (CAR) T cell generation using the company’s VivoVec platform. The data include results from the first four NHPs treated in an ongoing study… Read More

#Cancer Research #News

Cancer research
#AACR #Cancer research #Cancer treatment

AACR Cancer Progress Report with spotlight on cancer immunotherapy 

On 13 September 2023, the American Association for Cancer Research (AACR) released the AACR Cancer Progress Report 2023: Advancing the Frontiers of Cancer Science and Medicine.   This report chronicles how basic, translational, clinical cancer research, and cancer-related population sciences — supported by federal investments in the National Institutes of Health… Read More

#Business & Investment #Cancer Research #News #Regulatory